U.S. Specialty Stores Stock News

NYSE:RH
NYSE:RHSpecialty Retail

How RH’s Q1 2026 Earnings Call and Letter May Reframe the RH (RH) Turnaround Story

RH recently announced it will report first quarter fiscal 2026 results for the period ended May 2, 2026, on June 11, 2026, after market close, accompanied by a shareholder letter from CEO Gary Friedman and a live conference call and webcast. This update comes as RH faces multi-year declines in revenue and earnings per share, making the forthcoming commentary on its evolution and performance particularly important for understanding how it is addressing these pressures. We’ll now explore how...
NYSE:NGVT
NYSE:NGVTChemicals

Evaluating Ingevity (NGVT) After Recent Share Price Volatility And A 21.7% Undervaluation Claim

What the latest move in Ingevity (NGVT) means for investors Ingevity (NGVT) has been drawing attention after recent trading, with the stock closing at $66.93 and showing mixed short term performance, including a move down of about 12% over the past month. See our latest analysis for Ingevity. Recent trading has been choppy, with a 1-day share price return of 1.42% and a 30-day share price return down 11.5%. However, year to date the share price return is 11.38% and the 1-year total...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Is Marex Group (MRX) Quietly Reframing Its Risk Appetite With a Fintech Insider on the Board?

Marex Group plc has appointed fintech entrepreneur and veteran credit and fixed income banker Georges Assi to its Group Board and Risk Committee, effective 8 June 2026. His combination of technology-enabled lending experience at Sigma Lending and deep private credit expertise from Naviter Capital adds specialist risk and credit insight directly into Marex’s board-level oversight. We’ll now examine how bringing a fintech-focused credit specialist onto the board and Risk Committee could...
NasdaqGM:URGN
NasdaqGM:URGNBiotechs

How Resolving Jelmyto Patent Litigation And Setting 2030 Generic Entry At UroGen Pharma (URGN) Has Changed Its Investment Story

In June 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. announced a settlement and license agreement with Teva Pharmaceuticals resolving their U.S. patent litigation over Jelmyto, granting Teva a non-exclusive license to sell a generic version from 15 September 2030, subject to FDA approval and regulatory review. This agreement reduces legal uncertainty around UroGen’s key urothelial cancer therapy while defining a clear timeline for eventual generic competition. We’ll now examine how...
NYSE:CE
NYSE:CEChemicals

Assessing Celanese (CE) Valuation After Recent Share Price Weakness

Celanese (CE) is back in focus after recent trading pressure, with the stock down 14% over the past month and 3% over the past 3 months, drawing attention to its current valuation. See our latest analysis for Celanese. The recent 14% 30-day share price decline follows a stronger year-to-date share price return of 16.41%, while the 1-year total shareholder return is down 13.57%, suggesting that momentum has recently weakened. If you want to widen your search beyond chemicals and materials,...
NYSE:PPL
NYSE:PPLElectric Utilities

Assessing PPL (PPL) Valuation As Recent Trading Weakness Meets Conflicting Fair Value Estimates

PPL (PPL) has drawn fresh attention after recent trading left the stock down about 2% over the past month and about 7% over the past 3 months. This has prompted investors to reassess its utilities profile. See our latest analysis for PPL. Recent trading has been mixed, with the share price down 6.58% over the past 90 days but supported by a 7.53% 1 year total shareholder return and a 44.68% 3 year total shareholder return. This suggests longer term holders have seen steadier gains than short...
NasdaqGS:EXC
NasdaqGS:EXCElectric Utilities

Does Exelon’s Bigger 2026–2029 Grid Plan Shift the Risk Profile for EXC Investors?

In the first quarter of 2026, Exelon reported revenue and adjusted net income that exceeded expectations and increased year over year, while reaffirming its full-year 2026 earnings outlook. The company also lifted its 2026–2029 capital plan to US$41.70 billion, underscoring a larger grid and infrastructure program that now depends more heavily on regulatory approval and financing conditions. Next, we’ll examine how Exelon’s expanded US$41.70 billion infrastructure plan may reshape its...
NYSE:TKO
NYSE:TKOEntertainment

A Look At TKO Group Holdings (TKO) Valuation After Dividend Declaration And US$1b Buyback Approval

Dividend and buyback moves put income and capital return in focus TKO Group Holdings (TKO) is back on investor radars after its board declared a quarterly cash dividend of US$0.79 per Class A share, tied to an aggregate US$150 million distribution. The payout, scheduled for June 30, 2026 to shareholders of record on June 15, 2026, comes alongside an additional US$1 billion share repurchase authorization and recently reported growth in revenue, net income and adjusted EBITDA. See our latest...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Oklo (OKLO) Valuation Check As ARMEC Acquisition Advances Reactor Manufacturing And Commercialization Plans

Oklo (OKLO) has agreed to acquire ARMEC, a precision manufacturing and engineering firm. The deal is expected to give the company tighter control over reactor and fuel component production, as well as quicker feedback between design and fabrication. See our latest analysis for Oklo. Oklo’s recent ARMEC deal lands after a volatile stretch where the stock’s 1-day share price return of 1.46% contrasts with a share price that is down 24.24% year to date. Its 3-year total shareholder return of...
NasdaqGS:CBRS
NasdaqGS:CBRSSemiconductor

US Stock Market Today S&P 500 Futures Edge Higher On Strong Jobs Data

The Morning Bull - US Market Morning Update Tuesday, Jun, 9 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 minis ahead roughly 0.6%, as investors weigh strong US jobs data against rising borrowing costs. Payrolls in May added 172,000 jobs versus 85,000 expected and the unemployment rate held at 4.3%, a combination that keeps talk of a possible year end interest rate hike alive. At the same time, the 10 year Treasury...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

Assessing Workday (WDAY) Valuation After Expanded AI Agent Launches And New Cloud Partnerships

Workday (WDAY) has rolled out a broad set of AI releases, including Agent Passport for testing and monitoring AI agents, new developer tools in Workday Build, and deeper integrations with AWS and Google Cloud. See our latest analysis for Workday. The recent AI launches and new cloud partnerships have come at a time of weak share price performance, with the stock down 30.1% year to date and the 1-year total shareholder return declining 43.2%. However, a 12.5% 1-month share price return...
NasdaqGS:WTW
NasdaqGS:WTWInsurance

How WTW’s New DFSA Licence in Dubai Will Impact Willis Towers Watson (WTW) Investors

In early June 2026, WTW Investments (DIFC) Limited received approval from the Dubai Financial Services Authority to operate within the Dubai International Financial Centre, enabling the firm to locally provide its full range of regulated investment capabilities across expanding segments such as wealth management, family offices and workplace savings. This DFSA licence gives WTW a locally anchored platform in a major global financial hub, potentially deepening client relationships in the...
NYSEAM:CET
NYSEAM:CETCapital Markets

How Investors May Respond To Central Securities (CET) Tax-Efficient $0.31 Dividend Declaration

Earlier this month, Central Securities Corporation’s Board declared a US$0.31 per-share common stock dividend, scheduled for payment on June 26, 2026, with ex-dividend and record dates of June 12, 2026. An interesting feature of this distribution is its tax mix, with US$0.06 expected to be treated as ordinary income and US$0.25 as long-term capital gain, subject to final year-end confirmation. We’ll now explore how this dividend’s blend of ordinary income and long-term capital gain shapes...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

A Look At Palantir Technologies (PLTR) Valuation After AIPCon 10 And Raised Guidance

Palantir Technologies (PLTR) is back in focus after reporting 85% year over year revenue growth, raising full year guidance, and using AIPCon 10 to showcase deeper adoption of its AI platforms. See our latest analysis for Palantir Technologies. Despite the strong AIPCon 10 news flow and raised guidance, Palantir’s share price is down 18.7% year to date, with a 7 day share price return of a 15.05% decline. The 3 year total shareholder return is around 7x, suggesting long term momentum remains...
NasdaqCM:ABAT
NasdaqCM:ABATMetals and Mining

American Battery Technology (ABAT) Is Up 6.1% After DOE Reinstates US$115M Grant For Lithium Refinery

American Battery Technology Company recently won its appeal with the U.S. Department of Energy, securing full reinstatement of a US$115 million grant to fund the first phase of its Tonopah Flats Lithium Project refinery, with all technical and commercial milestones preserved and the schedule adjusted for the review-related delay. This decision follows multi-administration federal backing and a Pre-Feasibility Study outlining a long-life lithium project, highlighting sustained government...
NYSE:VFC
NYSE:VFCLuxury

Assessing V.F (VFC) Valuation After Recent Share Price Weakness And Turnaround Hopes

Recent performance snapshot V.F (VFC) has drawn investor attention after a mixed stretch for the stock, with the price at $16.62 and returns down 12% over the past month and about 2% over the past 3 months. See our latest analysis for V.F. Looking beyond the recent pullback, V.F's 1 year total shareholder return of 30.63% contrasts with a softer year to date share price return of an 8.48% decline. This suggests momentum has faded and recent moves may reflect changing views on future growth...
NYSE:GPK
NYSE:GPKPackaging

A Look At Graphic Packaging Holding (GPK) Valuation After Recent Share Price Weakness

Why Graphic Packaging Holding (GPK) Is Drawing Investor Attention Graphic Packaging Holding (GPK) is back on investor radars after recent trading left the stock around $10.52, with returns down over the past year but slightly positive in the past 3 months. See our latest analysis for Graphic Packaging Holding. Recent trading has been choppy, with the latest 7 day share price return down 6.16% and the year to date share price return down 30.56%. The 1 year total shareholder return has declined...
NasdaqGM:VCYT
NasdaqGM:VCYTBiotechs

Assessing Veracyte (VCYT) Valuation After New Prosigna Launch And Decipher Prostate Clinical Milestones

Veracyte (VCYT) is in focus after a busy period of clinical milestones, led by the U.S. commercial launch of its Prosigna Breast Risk of Recurrence test and new Phase III data across breast and prostate cancer. See our latest analysis for Veracyte. Despite a small pullback in the latest session, with the 1 day share price return down 3%, Veracyte’s 30 day share price return of 16.95% and 90 day share price return of 44.2% sit alongside a 1 year total shareholder return of 69.73%. This...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

Should Xeris Biopharma’s Q1 Beat and Director Stock Moves Prompt a Fresh Look From XERS Investors?

In early June 2026, Xeris Biopharma director Marla Persky sold 15,500 shares under a Rule 10b5-1 plan, then received new restricted stock units and stock options as part of the company’s 2018 Stock Option and Incentive Plan. Around the same time, Xeris Biopharma reported a 38% year-on-year increase in Q1 2026 revenue and earnings per share above market expectations, underscoring stronger-than-anticipated operating momentum. Now we’ll examine how Xeris’s better-than-expected Q1 revenue...
NasdaqGM:AIP
NasdaqGM:AIPSoftware

Is Arteris (AIP) Overvalued After Its Powerful One Year Share Price Run

Arteris stock performance snapshot Arteris (AIP) has drawn investor attention recently as its stock shows mixed short term moves, with a gain over the past month contrasted by a decline over the past week. See our latest analysis for Arteris. That short term pullback sits against a much stronger backdrop, with a 30 day share price return of 10.67%, a 90 day share price return of 131.21%, and a very large 1 year total shareholder return of 340.20%. Taken together, these figures suggest...
NYSE:OMF
NYSE:OMFConsumer Finance

Assessing OneMain Holdings (OMF) Valuation As Legal Risks And Insider Selling Shape Investor Attention

Why OneMain Holdings Is Back in Focus OneMain Holdings (OMF) is back on investor radars after perceived undervaluation met a cluster of risk signals, including weak financial strength scores, insider selling, legal overhang, and pressure in nonprime lending. See our latest analysis for OneMain Holdings. Recent price moves show this tension clearly. The share price is down 3.6% over the past month and down 21.7% year to date. However, 1 year and 3 year total shareholder returns of 10.1% and...
NasdaqGS:HST
NasdaqGS:HSTHotel and Resort REITs

A Look At Host Hotels & Resorts (HST) Valuation After Sector Rotation And Supportive Macro Tailwinds

Stock move tied to sector rotation and macro tailwinds Host Hotels & Resorts (HST) stock moved as investors shifted money from technology stocks into real estate investment trusts, supported by a strong U.S. jobs report and declining mortgage rates that aided sentiment toward commercial real estate. See our latest analysis for Host Hotels & Resorts. At a share price of $24.44, HST has seen momentum build, with a 30-day share price return of 9.74%, a 90-day share price return of 26.96% and a...
NasdaqGM:CDNA
NasdaqGM:CDNABiotechs

Assessing CareDx (CDNA) Valuation After Recent Share Price Volatility And Rebuilding Momentum

How CareDx stock has been performing CareDx (CDNA) has traded around $21.95 recently, with mixed short term returns and stronger performance over the past 3 years, creating an interesting backdrop for investors assessing risk and potential reward. See our latest analysis for CareDx. Recent trading has been choppy, with the share price down 1.35% over the last day and 3.73% over the past week. Despite this, the stock is still showing a 29.27% 90 day share price return and a 164.46% 3 year...
NYSE:DY
NYSE:DYConstruction

A Look At Dycom Industries (DY) Valuation After Strong Q1 Results And Raised 2027 Guidance

Dycom Industries (DY) stock has been in focus after the company reported first quarter revenue of US$1,964.78 million and net income of US$91.29 million, along with higher full year fiscal 2027 revenue guidance. See our latest analysis for Dycom Industries. Despite a dip of about 1.6% in the 1 day share price return and a 7 day share price return down roughly 7.1%, Dycom’s 30 day and 90 day share price returns of 7.1% and 26.4%, alongside a 1 year total shareholder return of 92.6%, point to...